Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 11/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 10/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.44 |
| ▸ | AKT1 | P31749 | 1/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1326713 | 0.83 | BCL2A1 (0.46) | BCL2A1SLC6A4SLC6A2SLC6A3ADRB2 | |
| SCHEMBL1327427 | 0.83 | BCL2A1 (0.43) | BCL2A1SLC6A4SLC6A2SLC6A3ADRB2 | |
| SCHEMBL3590453 | 0.82 | SLC6A4 (0.40) | SLC6A4SLC6A2SLC6A3CHRM1 | |
| SCHEMBL6258817 | 0.81 | IDO1 (0.49) | SLC6A4SLC6A2SLC6A3CHRM1GAA | |
| SCHEMBL493536 | 0.81 | BCL2A1 (0.45) | BCL2A1SLC6A4SLC6A2SLC6A3ADRB2 | |
| SCHEMBL4091462 | 0.80 | BCL2A1 (0.44) | BCL2A1SLC6A4SLC6A2SLC6A3ADRB2 | |
| SCHEMBL13903208 | 0.79 | GAA (0.47) | SLC6A4SLC6A2SLC6A3CHRM1GAA | |
| SCHEMBL17900515 | 0.79 | GAA (0.47) | SLC6A4SLC6A2SLC6A3CHRM1GAA | |
| SCHEMBL493821 | 0.79 | BCL2A1 (0.40) | BCL2A1SLC6A4SLC6A2SLC6A3ADRB2 | |
| SCHEMBL1326749 | 0.79 | BCL2A1 (0.43) | BCL2A1SLC6A4SLC6A2SLC6A3GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7728028-B2 | Substituted imidazoline compounds | GRUENENTHAL GMBH (DE) | 2010-06-01 | — | — | US | disclosed |
| US-20090048323-A1 | SUBSTITUTED IMIDAZOLINE COMPOUNDS | GRUENENTHAL GMBH (DE) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048323-A1 | SUBSTITUTED IMIDAZOLINE COMPOUNDS | ITCH, OPRK1, ALDH1A1 | BCL2A1 4352/4885SLC6A4 274/4885SLC6A2 355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.